Mga Batayang Estadistika
| LEI | 549300H8TYEUVTW14A54 |
| CIK | 1668397 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Medpace Holdings, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: |
|
| July 21, 2025 |
Medpace Holdings, Inc. Reports Second Quarter 2025 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Michael Maley 513.579.9911 x12831 [email protected] Medpace Holdings, Inc. Reports Second Quarter 2025 Results •Revenue of $603.3 million in the second quarter of 2025 increased 14.2% from revenue of $528.1 million for the comparable prior-year period, representing a backlog |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 21, 2025 |
Amendment No. 9 dated July 17, 2025 to Loan Documents Exhibit 10.1 Amendment No. 9 to Loan Documents THIS AMENDMENT NO. 9 TO LOAN DOCUMENTS (this “Amendment”) is made as of July 17, 2025, by and between MEDPACE, INC., an Ohio corporation (the “Borrower”), and PNC BANK, NATIONAL ASSOCIATION (the “Bank”). BACKGROUND A. The Borrower or another obligor has executed and delivered to the Bank (or a predecessor which is now known by the Bank’s name as set f |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2025 MEDPACE HOLDINGS, INC. |
|
| May 16, 2025 |
Medpace Holdings, Inc. 2016 Amended and Restated Incentive Award Plan EX-10.1 Exhibit 10.1 MEDPACE HOLDINGS, INC. 2016 AMENDED AND RESTATED INCENTIVE AWARD PLAN (As Amended and Restated, Effective as of February 6, 2025) ARTICLE 1. PURPOSE The purpose of the Medpace Holdings, Inc. 2016 Amended and Restated Incentive Award Plan (as it may be amended or restated from time to time, the “Plan”) is to promote the success and enhance the value of Medpace Holdings, Inc. (t |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: |
|
| April 21, 2025 |
Exhibit 10.1 Amendment No. 8 to Loan Documents THIS AMENDMENT NO. 8 TO LOAN DOCUMENTS (this “Amendment”) is made as of April 18, 2025, by and between MEDPACE, INC., an Ohio corporation (the “Borrower”), and PNC BANK, NATIONAL ASSOCIATION (the “Bank”). BACKGROUND A. The Borrower or another obligor has executed and delivered to the Bank (or a predecessor which is now known by the Bank’s name as set |
|
| April 21, 2025 |
Medpace Holdings, Inc. Reports First Quarter 2025 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Michael Maley 513.579.9911 x12831 [email protected] Medpace Holdings, Inc. Reports First Quarter 2025 Results •Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog co |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2025 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| April 2, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy S |
|
| March 31, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2025 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 31, 2025 |
Exhibit 10.1 Amendment No. 7 to Loan Documents THIS AMENDMENT NO. 7 TO LOAN DOCUMENTS (this “Amendment”) is made as of March 28, 2025, by and between MEDPACE, INC., an Ohio corporation (the “Borrower”), and PNC BANK, NATIONAL ASSOCIATION (the “Bank”). BACKGROUND A. The Borrower or another obligor has executed and delivered to the Bank (or a predecessor which is now known by the Bank’s name as set |
|
| February 11, 2025 |
List of Subsidiaries of Medpace Holdings, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES OF MEDPACE HOLDINGS, INC. Jurisdiction of Organization Entity Name Delaware Medpace Acquisition, Inc. Delaware Medpace IntermediateCo, Inc. Ohio Imagepace, LLC Ohio Medpace Clinical Pharmacology LLC Ohio Medpace, Inc. Ohio Medpace Reference Laboratories LLC |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001- |
|
| February 10, 2025 |
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Michael Maley 513.579.9911 x12831 [email protected] Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results •Revenue of $536.6 million in the fourth quarter of 2024 increased 7.7% from revenue of $498.4 million for the comparable prior-year period, represent |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 22, 2024 |
Form of Medpace Holdings, Inc. 2016 Incentive Award Exhibit 10.2 MEDPACE HOLDINGS, INC. 2016 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Medpace Holdings, Inc., a Delaware corporation (the “Company”), pursuant to its 2016 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the number of Restricted Stock Units (the “RSUs”) set forth below. The RSUs are subject to |
|
| October 22, 2024 |
Exhibit 10.1 MEDPACE HOLDINGS, INC. 2016 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT Medpace Holdings, Inc., a Delaware corporation (the “Company”), pursuant to its 2016 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) an option to purchase the number of Shares set forth below (the “Option”). The |
|
| October 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file num |
|
| October 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2024 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 21, 2024 |
Medpace Holdings, Inc. Reports Third Quarter 2024 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Michael Maley 513.579.9911 x12831 [email protected] Medpace Holdings, Inc. Reports Third Quarter 2024 Results •Revenue of $533.3 million in the third quarter of 2024 increased 8.3% from revenue of $492.5 million for the comparable prior-year period, representing a backlog co |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: |
|
| July 22, 2024 |
Medpace Holdings, Inc. Reports Second Quarter 2024 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] Medpace Holdings, Inc. Reports Second Quarter 2024 Results •Revenue of $528.1 million in the second quarter of 2024 increased 14.6% from revenue of $460.9 million for the comparable prior-year period, representing a backl |
|
| July 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 28, 2024 MEDPACE HOLDINGS, INC. |
|
| May 21, 2024 |
Restated Certificate of Incorporation Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF MEDPACE HOLDINGS, INC. (Originally incorporated on February 18, 2014 under the name Camargo Holdings, Inc.) FIRST: The name of the corporation (hereinafter called the “Corporation”) is: Medpace Holdings, Inc. SECOND: The address of the registered office of the Corporation in the State of Delaware is Corporation Trust Center, 1209 Orange Street, |
|
| May 21, 2024 |
Second Amended and Restated Bylaws Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF MEDPACE HOLDINGS, INC. Dated as of May 17, 2024 Table of Contents Page ARTICLE I MEETINGS OF STOCKHOLDERS 4 Section 1.01 Place of Meetings 4 Section 1.02 Annual Meetings 4 Section 1.03 Special Meetings 4 Section 1.04 Notice of Meetings 4 Section 1.05 Adjournments 4 Section 1.06 Quorum 4 Section 1.07 Organization 5 Section 1.08 Voting; Proxies 5 Sec |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2024 MEDPACE HOLDINGS, INC. |
|
| April 23, 2024 |
Exhibit 10.1 MEDPACE HOLDINGS, INC. 2016 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT Medpace Holdings, Inc., a Delaware corporation (the “Company”), pursuant to its 2016 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) an option to purchase the number of Shares set forth below (the “Option”). The |
|
| April 23, 2024 |
Form of Medpace Holdings, Inc. 2016 Incentive Award Plan Restricted Stock Unit Award Grant Notice Exhibit 10.2 MEDPACE HOLDINGS, INC. 2016 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Medpace Holdings, Inc., a Delaware corporation (the “Company”), pursuant to its 2016 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the number of Restricted Stock Units (the “RSUs”) set forth below. The RSUs are subject to |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 22, 2024 |
Medpace Holdings, Inc. Reports First Quarter 2024 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] Medpace Holdings, Inc. Reports First Quarter 2024 Results •Revenue of $511.0 million in the first quarter of 2024 increased 17.7% from revenue of $434.1 million for the comparable prior-year period, representing a backlog |
|
| April 3, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy S |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 29, 2024 |
Exhibit 10.1 Amendment No. 6 to Loan Documents THIS AMENDMENT NO. 6 TO LOAN DOCUMENTS (this “Amendment”) is made as of March 28, 2024, by and between MEDPACE, INC., an Ohio corporation (the “Borrower”), and PNC BANK, NATIONAL ASSOCIATION (the “Bank”). BACKGROUND A. The Borrower or another obligor has executed and delivered to the Bank (or a predecessor which is now known by the Bank’s name as set |
|
| March 20, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: x Preliminary Proxy S |
|
| March 8, 2024 |
MEDP / Medpace Holdings, Inc. / Troendle August J. - SC 13D/A Activist Investment SC 13D/A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 21)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 (CUSI |
|
| February 28, 2024 |
MEDP / Medpace Holdings, Inc. / Troendle August J. - SC 13D/A Activist Investment SC 13D/A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 20)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 (CUSI |
|
| February 13, 2024 |
Exhibit 97.1 MEDPACE HOLDINGS, INC. Incentive Compensation Recoupment Policy (the “Policy”) Adopted by the Board of Directors effective December 1, 2023. 1. Recoupment. If Medpace Holdings, Inc. (the “Company”) is required to prepare a Restatement, the Company’s board of directors (the “Board”) shall, unless the Board’s Compensation Committee determines it to be Impracticable, take reasonably prom |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001- |
|
| February 13, 2024 |
MEDP / Medpace Holdings, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01436-medpaceholdingsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Medpace Holdings Inc Title of Class of Securities: Common Stock CUSIP Number: 58506Q109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to desi |
|
| February 13, 2024 |
List of Subsidiaries of Medpace Holdings, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES OF MEDPACE HOLDINGS, INC. Jurisdiction of Organization Entity Name Delaware Medpace Acquisition, Inc. Delaware Medpace IntermediateCo, Inc. Ohio Imagepace, LLC Ohio Medpace Clinical Pharmacology LLC Ohio Medpace, Inc. Ohio Medpace Reference Laboratories LLC |
|
| February 13, 2024 |
Insider Trading Compliance Policy Exhibit 19.1 MEDPACE HOLDINGS, INC. INSIDER TRADING COMPLIANCE POLICY (Amended Effective October 20, 2023) This Insider Trading Compliance Policy (this "Policy") consists of seven sections: • Section I provides an overview; • Section II sets forth the policies of the Company prohibiting insider trading; • Section III explains insider trading; • Section IV consists of procedures that have been put |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2024 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 12, 2024 |
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Results •Revenue of $498.4 million in the fourth quarter of 2023 increased 26.5% from revenue of $394.1 million for the comparable prior-year period, repres |
|
| December 5, 2023 |
MEDP / Medpace Holdings Inc / Troendle August J. - SC 13D/A Activist Investment SC 13D/A 1 d611549dsc13da.htm SC 13D/A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 19)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file num |
|
| October 23, 2023 |
Medpace Holdings, Inc. Reports Third Quarter 2023 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] Medpace Holdings, Inc. Reports Third Quarter 2023 Results •Revenue of $492.5 million in the third quarter of 2023 increased 28.3% from revenue of $383.7 million for the comparable prior-year period, representing a backlog |
|
| October 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2023 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 22, 2023 |
MEDP / Medpace Holdings Inc / Troendle August J. - SC 13D/A Activist Investment SC 13D/A 1 d541174dsc13da.htm SC 13D/A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 18)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class |
|
| September 22, 2023 |
February 2023 Rule 10b5-1 Stock Trading Plan of Medpace Investors, LLC EX-3.2 3 d541174dex32.htm EX-3.2 Exhibit 3.2 Rule 10b5-l Trading Plan This Trading Plan (the “Trading Plan”) is entered into on 02/20/2023 (“Seller’s Adoption Date”) (MM/DD/YYYY) between Medpace Investors LLC (“Seller”) and UBS Financial Services Inc. (“UBSFS“) for the purpose of selling, in accordance with Rule 10b5-l (c)(1) of the Securities Exchange Act of 1934 as amended (the “Exchan |
|
| September 22, 2023 |
May 2023 Rule 10b5-1 Stock Trading Plan of Medpace Investors, LLC EX-3.1 2 d541174dex31.htm EX-3.1 Exhibit 3.1 Rule 10b5-l Trading Plan This Trading Plan (the “Trading Plan”) is entered into on 05/01/2023 (“Seller’s Adoption Date”) (MM/DD/YYYY) between Medpace Investors LLC (“Seller”) and UBS Financial Services Inc. (“UBSFS”) for the purpose of selling, in accordance with Rule 10b5-l (c)( 1) of the Securities Exchange Act of 193-1 as amended (the “Exc |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2023 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 24, 2023 |
Medpace Holdings, Inc. Reports Second Quarter 2023 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] Medpace Holdings, Inc. Reports Second Quarter 2023 Results •Revenue of $460.9 million in the second quarter of 2023 increased 31.2% from revenue of $351.2 million for the comparable prior-year period, representing a backl |
|
| May 19, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2023 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 24, 2023 |
Medpace Holdings, Inc. Reports First Quarter 2023 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] Medpace Holdings, Inc. Reports First Quarter 2023 Results •Revenue of $434.1 million in the first quarter of 2023 increased 31.2% from revenue of $330.9 million for the comparable prior-year period, representing a backlog |
|
| April 5, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy S |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 31, 2023 |
Amendment No. 5 dated March 31, 2023 to Loan Documents Exhibit 10.1 Amendment No. 5 to Loan Documents THIS AMENDMENT NO. 5 TO LOAN DOCUMENTS (this “Amendment”) is made as of March 31, 2023 by and between MEDPACE, INC., an Ohio corporation (the “Borrower”), and PNC BANK, NATIONAL ASSOCIATION (the “Bank”). BACKGROUND A. The Borrower or another obligor has executed and delivered to the Bank (or a predecessor which is now known by the Bank’s name as set f |
|
| February 14, 2023 |
List of Subsidiaries of Medpace Holdings, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES OF MEDPACE HOLDINGS, INC. Jurisdiction of Organization Entity Name Delaware Medpace Acquisition, Inc. Delaware Medpace IntermediateCo, Inc. Ohio Imagepace, LLC Ohio Medpace Clinical Pharmacology LLC Ohio Medpace, Inc. Ohio Medpace Reference Laboratories LLC |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001- |
|
| February 14, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) MEDPACE HOLDINGS, INC. |
|
| February 14, 2023 |
Medpace Holdings, Inc. Non-Employee Director Compensation Policy revised October 21, 2022 Exhibit 10.10 Medpace Holdings, Inc. Non-Employee Director Compensation Policy (Revised October 21, 2022) Non-employee members of the board of directors (the “Board”) of Medpace Holdings, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation described in this Po |
|
| February 14, 2023 |
As filed with the Securities and Exchange Commission on February 14, 2023 Table of Contents As filed with the Securities and Exchange Commission on February 14, 2023 Registration No. |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 13, 2023 |
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2022 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2022 Results •Revenue of $394.1 million in the fourth quarter of 2022 increased 27.7% from revenue of $308.6 million for the comparable prior-year period, repres |
|
| February 9, 2023 |
MEDP / Medpace Holdings Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01402-medpaceholdingsinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Medpace Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 58506Q109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to des |
|
| January 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 16, 2023 MEDPACE HOLDINGS, INC. |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31, 2022 MEDPACE HOLDINGS, INC. |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file num |
|
| October 24, 2022 |
Medpace Holdings, Inc. Reports Third Quarter 2022 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] Medpace Holdings, Inc. Reports Third Quarter 2022 Results •Revenue of $383.7 million in the third quarter of 2022 increased 29.8% from revenue of $295.6 million for the comparable prior-year period, representing a backlog |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2022 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 21, 2022 |
MEDP / Medpace Holdings Inc / Troendle August J. - SC 13D/A Activist Investment United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(a) and Amendments Thereto Filed Pursuant to ? 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 17)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 (CUSIP Number) |
|
| September 13, 2022 |
Amendment to Rule 10b5-l Trading Plan Exhibit 3 Amendment to Rule 10b5-l Trading Plan The Trading Plan dated 3/17/2022 and amended 5/3/2022 (the ?Trading Plan?) entered into between Medpace Investors LLC (?Purchaser?) and UBSFS, acting as agent, for the purpose of establishing a trading plan that complies with Rule 10b5-1(c)(1) under the Securities Exchange Act of 1934, as amended (the ?Exchange Act?) is amended on August 15, 2022 as |
|
| September 13, 2022 |
MEDP / Medpace Holdings Inc / Troendle August J. - SC 13D/A Activist Investment United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(a) and Amendments Thereto Filed Pursuant to ? 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 16)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 (CUSIP Number) |
|
| July 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace |
|
| July 25, 2022 |
Medpace Holdings, Inc. Reports Second Quarter 2022 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] Medpace Holdings, Inc. Reports Second Quarter 2022 Results ? Revenue of $351.2 million in the second quarter of 2022 increased 26.2% from revenue of $278.3 million for the comparable prior-year period, representing a back |
|
| July 25, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2022 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| July 6, 2022 |
Exhibit 3 Rule 10b5-l Trading Plan This Trading Plan (the ?Trading Plan?) is entered into on 3/17/22 (?Purchaser?s Adoption Date?) between Medpace Investors LLC (?Purchaser?) and UBS Financial Services Inc. |
|
| July 6, 2022 |
MEDP / Medpace Holdings Inc / Troendle August J. - SC 13D/A Activist Investment SC 13D/A 1 d337079dsc13da.htm SC 13D/A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 15)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 10, 2022 MEDPACE HOLDINGS, INC. |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2022 MEDPACE HOLDINGS, INC. |
|
| May 20, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2022 MEDPACE HOLDINGS, INC. |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace |
|
| April 25, 2022 |
Medpace Holdings, Inc. Reports First Quarter 2022 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] Medpace Holdings, Inc. Reports First Quarter 2022 Results ? Revenue of $330.9 million in the first quarter of 2022 increased 27.3% from revenue of $260.0 million for the comparable prior-year period, representing a backlo |
|
| April 25, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2022 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide |
|
| April 6, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy S |
|
| March 16, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 16, 2022 |
Amendment No. 4 dated March 15, 2022 to Loan Documents Amendment No. 4 to Loan Documents Exhibit 10.1 THIS AMENDMENT NO. 4 TO LOAN DOCUMENTS (this ?Amendment?) is made as of March 15, 2022 by and between MEDPACE, INC., an Ohio corporation (the ?Borrower?), and PNC BANK, NATIONAL ASSOCIATION (the ?Bank?). BACKGROUND A. The Borrower or another obligor has executed and delivered to the Bank (or a predecessor which is now known by the Bank?s name as set f |
|
| February 15, 2022 |
List of Subsidiaries of Medpace Holdings, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES OF MEDPACE HOLDINGS, INC. Jurisdiction of Organization Entity Name Delaware Medpace Acquisition, Inc. Delaware Medpace IntermediateCo, Inc. Ohio Imagepace, LLC Ohio Medpace Clinical Pharmacology LLC Ohio Medpace, Inc. Ohio Medpace Reference Laboratories LLC |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace Hold |
|
| February 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2022 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 14, 2022 |
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Results ? Revenue of $308.6 million in the fourth quarter of 2021 increased 18.8% from revenue of $259.7 million for the comparable prior-year period, repre |
|
| February 10, 2022 |
MEDP / Medpace Holdings Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Medpace Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 58506Q109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| December 29, 2021 |
Exhibit 10.1 Amendment No. 3 to Loan Documents THIS AMENDMENT NO. 3 TO LOAN DOCUMENTS (this ?Amendment?) is made as of December 27, 2021 by and between MEDPACE, INC., an Ohio corporation (the ?Borrower?), and PNC BANK, NATIONAL ASSOCIATION (the ?Bank?). BACKGROUND A. The Borrower or another obligor has executed and delivered to the Bank (or a predecessor which is now known by the Bank?s name as se |
|
| December 29, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 27, 2021 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 23, 2021 |
MEDP / Medpace Holdings Inc / Troendle August J. - SC 13D/A Activist Investment SC 13D/A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 14)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 (CUSI |
|
| December 23, 2021 |
Exhibit 3 Rule 10b5-1 Trading Plan This Trading Plan (the ?Trading Plan?) is entered into on 11/01/2021 (?Seller?s Adoption Date?) (MM/DD/YYYY) between Medpace Investors LLC (?Seller?) and UBS Financial Services Inc. |
|
| October 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Med |
|
| October 25, 2021 |
Medpace Holdings, Inc. Reports Third Quarter 2021 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] FOR IMMEDIATE RELEASE Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] Medpace Holdings, Inc. Reports Third Quarter 2021 Results ? Revenue of $295.6 million in the third quarter of 2021 increased 28.3% from revenue of $230.4 million for the comparable prior-year period, representing a backlo |
|
| October 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2021 Medpace Holdings, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 1, 2021 |
MEDP / Medpace Holdings Inc / Troendle August J. - SC 13D/A Activist Investment United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(a) and Amendments Thereto Filed Pursuant to ? 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 13)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 (CUSIP Number) |
|
| July 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace |
|
| July 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 26, 2021 MEDPACE HOLDINGS, INC. |
|
| July 26, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2021 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 26, 2021 |
Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] Medpace Holdings, Inc. Announces Senior Leadership Changes Appointment of Jesse Geiger as President and Kevin Brady as Chief Financial Officer CINCINNATI, OHIO, July 26, 2021 ? Medpace Holdings, Inc. (Nasdaq: MEDP) (?Medpace?) today announced |
|
| July 26, 2021 |
Medpace Holdings, Inc. Reports Second Quarter 2021 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Second Quarter 2021 Results ? Revenue of $278.3 million in the second quarter of 2021 increased 35.8% from revenue of $205.0 million for the comparable prior-year period, representing a back |
|
| July 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 22, 2021 MEDPACE HOLDINGS, INC. |
|
| June 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2021 MEDPACE HOLDINGS, INC. |
|
| May 14, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2021 MEDPACE HOLDINGS, INC. |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace |
|
| April 26, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2021 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commission F |
|
| April 26, 2021 |
Medpace Holdings, Inc. Reports First Quarter 2021 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports First Quarter 2021 Results ? Revenue of $260.0 million in the first quarter of 2021 increased 12.6% from revenue of $230.9 million for the comparable prior-year period, representing a backlo |
|
| April 21, 2021 |
Exhibit 3 Exhibit 3 Rule 10b5-l Trading Plan This Trading Plan (the “Trading Plan”) is entered into on 03/12/2021 (“Seller’s Adoption Date”) (MM/DD/YYYY) between Medpace Investors LLC (“Seller”) and UBS Financial Services Inc. |
|
| April 21, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(a) and Amendments Thereto Filed Pursuant to ? 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 12)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 (CUSIP Number) |
|
| March 30, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2021 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commission F |
|
| March 30, 2021 |
it UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 30, 2021 |
Exhibit 10.1 Amendment No. 2 to Loan Documents THIS AMENDMENT NO. 2 TO LOAN DOCUMENTS (this ?Amendment?) is made as of March 29, 2021 by and between MEDPACE, INC., an Ohio corporation (the ?Borrower?), and PNC BANK, NATIONAL ASSOCIATION (the ?Bank?). BACKGROUND A.The Borrower or another obligor has executed and delivered to the Bank (or a predecessor which is now known by the Bank?s name as set fo |
|
| February 16, 2021 |
Form of Indemnification Agreement Exhibit 10.13 INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made effective as of [ ? ], 20[ ? ] by and between Medpace Holdings, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors or in other capacities unless they are provided with adequ |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace Hold |
|
| February 16, 2021 |
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2020 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2020 Results ? Revenue of $259.7 million in the fourth quarter of 2020 increased 13.0% from revenue of $229.9 million for the comparable prior-year period, repre |
|
| February 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2021 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commissio |
|
| February 16, 2021 |
List of Subsidiaries of Medpace Holdings, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES OF MEDPACE HOLDINGS, INC. Jurisdiction of Organization Entity Name Delaware Medpace Acquisition, Inc. Delaware Medpace IntermediateCo, Inc. Ohio Imagepace, LLC Ohio Medpace Clinical Pharmacology LLC Ohio Medpace, Inc. Ohio Medpace Reference Laboratories LLC |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Medpace Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 58506Q109 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| December 21, 2020 |
EXHIBIT 4 Exhibit 4 Rule 10b5-1 Trading Plan This Trading Plan (the “Trading Plan”) is entered into on 12/03/2020 (“Seller’s Adoption Date”) (MM/DD/YY) between Medpace Investors LLC (“Seller”) and UBS Financial Services Inc. |
|
| December 21, 2020 |
SC 13D/A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 11)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 (CUSI |
|
| October 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2020 MEDPACE HOLDINGS, INC. |
|
| October 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Med |
|
| October 26, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2020 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commission |
|
| October 26, 2020 |
Medpace Holdings, Inc. Reports Third Quarter 2020 Results Exhibit 99.1 Investor Contact: Lauren Morris 513.579.9911 x11994 [email protected] Media Contact: Julie Hopkins 513.579.9911 x12627 [email protected] FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Third Quarter 2020 Results • Revenue of $230.4 million in the third quarter of 2020 increased 6.5% from revenue of $216.2 million for the comparable prior-year period, representing a backlog |
|
| August 14, 2020 |
MEDP / Medpace Holdings, Inc. / Troendle August J. - SC 13D/A #10 Activist Investment SC 13D/A #10 United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 10)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 ( |
|
| July 31, 2020 |
EX-99.7 Exhibit 7 Rule 10b5-1 Trading Plan This Trading Plan (the “Trading Plan”) is entered into on 03/04/2020 (“Seller’s Adoption Date”) (MM/DD/YYYY) between Medpace Investors LLC (“Seller”) and UBS Financial Services Inc. (“UBSFS”) for the purpose of selling, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934 as amended (the “Exchange Act”), shares of common stock of Me |
|
| July 31, 2020 |
MEDP / Medpace Holdings, Inc. / Troendle August J. - SC 13D/A #9 Activist Investment SC 13D/A #9 United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 9)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 (CU |
|
| July 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace |
|
| July 27, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2020 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 27, 2020 |
Medpace Holdings, Inc. Reports Second Quarter 2020 Results Exhibit 99.1 Media Contact: Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 [email protected] Investor Contact: [email protected] FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Second Quarter 2020 Results • Revenue of $205.0 million in the second quarter of 2020 decreased 4.3% from revenue of $214.1 million for the comparable prior-year period, representing a backlog conversi |
|
| May 21, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2020 MEDPACE HOLDINGS, INC. |
|
| May 8, 2020 |
MEDP / Medpace Holdings, Inc. / Troendle August J. - SC 13D/A Activist Investment SC 13D/A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 8)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 (CUSIP |
|
| April 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace |
|
| April 28, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2020 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commission F |
|
| April 28, 2020 |
Medpace Holdings, Inc. Reports First Quarter 2020 Results Exhibit 99.1 Media Contact: Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 [email protected] Investor Contact: [email protected] FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports First Quarter 2020 Results • Revenue of $230.9 million in the first quarter of 2020 increased 15.0% from revenue of $200.7 million for the comparable prior-year period, representing a backlog conversio |
|
| April 1, 2020 |
Exhibit 10.1 Amendment No. 1 to Loan Documents THIS AMENDMENT NO. 1 TO LOAN DOCUMENTS (this “Amendment”) is made as of March 30, 2020 by and between MEDPACE, INC., an Ohio corporation (the “Borrower”), and PNC BANK, NATIONAL ASSOCIATION (the “Bank”). BACKGROUND A.The Borrower or another obligor has executed and delivered to the Bank (or a predecessor which is now known by the Bank’s name as set fo |
|
| April 1, 2020 |
MEDP / Medpace Holdings, Inc. DEFA14A - - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 1, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2020 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commission F |
|
| April 1, 2020 |
MEDP / Medpace Holdings, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2020 Medpace Holdings, Inc. |
|
| February 25, 2020 |
As filed with the Securities and Exchange Commission on February 25, 2020 As filed with the Securities and Exchange Commission on February 25, 2020 Registration No. |
|
| February 25, 2020 |
List of Subsidiaries of Medpace Holdings, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES OF MEDPACE HOLDINGS, INC. Jurisdiction of Organization Entity Name Delaware Medpace Acquisition, Inc. Delaware Medpace IntermediateCo, Inc. Ohio Imagepace, LLC Ohio Medpace Clinical Pharmacology LLC Ohio Medpace, Inc. Ohio Medpace Reference Laboratories LLC |
|
| February 25, 2020 |
EX-4.3 2 medp-ex43177.htm EX-4.3 Exhibit 4.3 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 25, 2020, Medpace Holdings, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock. General The following description of our com |
|
| February 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace Hold |
|
| February 25, 2020 |
MEDP / Medpace Holdings, Inc. S-3ASR - - S-3ASR S-3ASR Table of Contents As filed with the Securities and Exchange Commission on February 25, 2020 Registration No. |
|
| February 24, 2020 |
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Results EX-99.1 2 medp-ex9916.htm EX-99.1 Exhibit 99.1 Media Contact: Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 [email protected] Investor Contact: [email protected] FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2019 Results • Revenue of $229.9 million in the fourth quarter of 2019 increased 19.7% from revenue of $192.1 million for the comparable p |
|
| February 24, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2020 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commissio |
|
| February 12, 2020 |
MEDP / Medpace Holdings, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Medpace Holdings Inc Title of Class of Securities: Common Stock CUSIP Number: 58506Q109 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| October 29, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Med |
|
| October 28, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2019 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commission |
|
| October 28, 2019 |
Medpace Holdings, Inc. Reports Third Quarter 2019 Results Exhibit 99.1 Media Contact: Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 [email protected] Investor Contact: [email protected] FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Third Quarter 2019 Results • Revenue of $216.2 million in the third quarter of 2019 increased 20.6% from revenue of $179.3 million for the comparable prior-year period, representing a backlog conversio |
|
| October 25, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 24, 2019 MEDPACE HOLDINGS, INC. |
|
| October 1, 2019 |
EX-10.1 2 medp-ex10116.htm EX-10.1 Exhibit 10.1 Loan Agreement THIS LOAN AGREEMENT (the “Agreement”), is entered into as of September 30, 2019, between MEDPACE, INC., an Ohio corporation (the “Borrower”), with an address at 5375 Medpace Way, Cincinnati Ohio 45227, and PNC BANK, NATIONAL ASSOCIATION (the “Bank”), with an address at 201 East Fifth Street, Cincinnati, Ohio 45202, Attn: Corporate Bank |
|
| October 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2019 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commissi |
|
| September 17, 2019 |
MEDP / Medpace Holdings, Inc. / Medpace Investors, Llc - SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) MEDPACE HOLDINGS, INC. (Name of Subject Company (Issuer)) MEDPACE INVESTORS, LLC & AUGUST J. TROENDLE (Names of Filing Persons (Offerors)) Options to Purchase Common Stock, Par Value $0.01 Pe |
|
| September 17, 2019 |
MEDP / Medpace Holdings, Inc. / Troendle August J. - SC 13D/A Activist Investment SC 13D/A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 7)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 (CUSIP |
|
| August 20, 2019 |
CORRESP F. Mark Reuter D: 513.579.6469 [email protected] August 20, 2019 VIA EDGAR Christina Chalk, Esq. Senior Special Counsel Securities and Exchange Commission Office of Mergers and Acquisitions 100 F. Street, NE Washington, D.C. 20549 Re: Medpace Holdings, Inc. Schedule 14D-9 filed August 8, 2019 File No. 5-89605 Dear Ms. Chalk: This firm represents Medpace Holdings, Inc. (“Medpace Holdings”) |
|
| August 20, 2019 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 To SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 MEDPACE HOLDINGS, INC. (Name of Subject Company) MEDPACE HOLDINGS, INC. (Name of Persons Filing Statement) Options to Purchase Common Stock, Par Value $0.01 Per Share (T |
|
| August 15, 2019 |
MEDP / Medpace Holdings, Inc. / Medpace Investors, Llc - SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) MEDPACE HOLDINGS, INC. (Name of Subject Company (Issuer)) MEDPACE INVESTORS, LLC & AUGUST J. TROENDLE (Names of Filing Persons (Offerors)) Options to Purchase Common Stock, Par Value $0.01 Pe |
|
| August 15, 2019 |
EX-99.(A).(2) 3 d756034dex99a2.htm EX-99.(A).(2) Exhibit (a)(2) FORM E-MAIL TO ELIGIBLE HOLDERS ANNOUNCING THE TENDER OFFER & DISTRIBUTING ELECTION FORM AND WITHDRAWAL NOTICE To: Eligible Holders From: Medpace Investors, LLC Date: August 15, 2019 Subject: Offer to Purchase for Cash Certain Outstanding and Vested Employee Stock Options Dear Eligible Holders: This e-mail is to notify you that Medpac |
|
| August 15, 2019 |
MEDPACE INVESTORS, LLC ELECTION FORM Instructions to Election Form EX-99.(a).(3) Exhibit (a)(3) MEDPACE INVESTORS, LLC ELECTION FORM Instructions to Election Form To elect to participate in the offer to purchase for cash certain employee stock options (the “Offer”), you must submit an Election Form in accordance with these instructions and the Offer to Purchase, dated August 15, 2019 (the “Offer to Purchase”). In order to participate in the Offer, a completed, si |
|
| August 15, 2019 |
EX-99.(a).(1) Table of Contents Exhibit (a)(1) MEDPACE INVESTORS, LLC OFFER TO PURCHASE FOR CASH VESTED EMPLOYEE STOCK OPTIONS OF MEDPACE HOLDINGS, INC. THIS OFFER AND ALL WITHDRAWAL RIGHTS EXPIRE ON SEPTEMBER 13, 2019 AT 11:59 P.M., EASTERN TIME, UNLESS THE OFFER PERIOD IS EXTENDED AUGUST 15, 2019 Medpace Investors, LLC, a Delaware limited liability company (“Medpace Investors”) and August J. Tro |
|
| August 15, 2019 |
EX-99.(a).(12) Exhibit (a)(12) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Eligible Options (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely by the Offer to Purchase, dated as of August 15, 2019, and the related Election Form and any amendments or supp |
|
| August 15, 2019 |
MEDPACE INVESTORS, LLC WITHDRAWAL NOTICE Instructions for Withdrawal Notice EX-99.(a).(4) Exhibit (a)(4) MEDPACE INVESTORS, LLC WITHDRAWAL NOTICE Instructions for Withdrawal Notice You should submit this Withdrawal Notice only if you previously submitted an Election Form in connection with our offer to purchase outstanding and vested employee stock options for cash (the “Offer”) and now no longer wish to tender your Eligible Options. In order to withdraw your Eligible Opt |
|
| August 8, 2019 |
MEDP / Medpace Holdings, Inc. SC 14D9 - - SC 14D9 SC 14D9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14D-9 (RULE 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 MEDPACE HOLDINGS, INC. (Name of Subject Company) MEDPACE HOLDINGS, INC. (Name of Persons Filing Statement) Options to Purchase Common Stock, Par Value $0.01 Per Share (Title of Class of Secu |
|
| August 7, 2019 |
MEDP / Medpace Holdings, Inc. / Medpace Investors, Llc - SC TO-T/A SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) MEDPACE HOLDINGS, INC. (Name of Subject Company (Issuer)) MEDPACE INVESTORS, LLC & AUGUST J. TROENDLE (Names of Filing Persons (Offerors)) Options to Purchase Common Stock, Par Value $0.01 Pe |
|
| August 7, 2019 |
EX-99.(a).(2) Exhibit (a)(2) FORM E-MAIL TO ELIGIBLE EMPLOYEES ANNOUNCING THE TENDER OFFER & DISTRIBUTING ELECTION FORM AND WITHDRAWAL NOTICE To: Eligible Employees From: Medpace Investors, LLC Date: August 7, 2019 Subject: Offer to Purchase for Cash Certain Outstanding and Vested Employee Stock Options Dear Eligible Employees: This e-mail is to notify you that Medpace Investors, LLC (“Medpace Inv |
|
| August 7, 2019 |
EX-99.(A).(1) 2 d756034dex99a1.htm EX-99.(A).(1) Table of Contents Exhibit (a)(1) MEDPACE INVESTORS, LLC OFFER TO PURCHASE FOR CASH VESTED EMPLOYEE STOCK OPTIONS OF MEDPACE HOLDINGS, INC. THIS OFFER AND ALL WITHDRAWAL RIGHTS EXPIRE ON SEPTEMBER 5, 2019 AT 11:59 P.M., EASTERN TIME, UNLESS THE OFFER PERIOD IS EXTENDED AUGUST 7, 2019 Medpace Investors, LLC, a Delaware limited liability company (“Medp |
|
| August 7, 2019 |
MEDPACE INVESTORS, LLC WITHDRAWAL NOTICE Instructions for Withdrawal Notice EX-99.(A).(4) 5 d756034dex99a4.htm EX-99.(A).(4) Exhibit (a)(4) MEDPACE INVESTORS, LLC WITHDRAWAL NOTICE Instructions for Withdrawal Notice You should submit this Withdrawal Notice only if you previously submitted an Election Form in connection with our offer to purchase outstanding and vested employee stock options for cash (the “Offer”) and now no longer wish to tender your Eligible Options. In |
|
| August 7, 2019 |
EX-99.(A).(12) 6 d756034dex99a12.htm EX-99.(A).(12) Exhibit (a)(12) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Eligible Options (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely by the Offer to Purchase, dated as of August 7,2019, and the related Elect |
|
| August 7, 2019 |
MEDPACE INVESTORS, LLC ELECTION FORM Instructions to Election Form EX-99.(A).(3) 4 d756034dex99a3.htm EX-99.(A).(3) Exhibit (a)(3) MEDPACE INVESTORS, LLC ELECTION FORM Instructions to Election Form To elect to participate in the offer to purchase for cash certain employee stock options (the “Offer”), you must submit an Election Form in accordance with these instructions and the Offer to Purchase, dated August 7, 2019 (the “Offer to Purchase”). In order to partici |
|
| August 5, 2019 |
MEDPACE INVESTORS, LLC WITHDRAWAL NOTICE Instructions for Withdrawal Notice EX-99.(A).(4) 5 d756034dex99a4.htm EX-99.(A).(4) Exhibit (a)(4) MEDPACE INVESTORS, LLC WITHDRAWAL NOTICE Instructions for Withdrawal Notice You should submit this Withdrawal Notice only if you previously submitted an Election Form in connection with our offer to purchase outstanding and vested employee stock options for cash (the “Offer”) and now no longer wish to tender your Eligible Options. In |
|
| August 5, 2019 |
EX-99.(a).(2) Exhibit (a)(2) FORM E-MAIL TO ELIGIBLE EMPLOYEES ANNOUNCING THE TENDER OFFER & DISTRIBUTING ELECTION FORM AND WITHDRAWAL NOTICE To: Eligible Employees From: Medpace Investors, LLC Date: August 6, 2019 Subject: Offer to Purchase for Cash Certain Outstanding and Vested Employee Stock Options Dear Eligible Employees: This e-mail is to notify you that Medpace Investors, LLC (“Medpace Inv |
|
| August 5, 2019 |
EX-99.(a).(1) Table of Contents Exhibit (a)(1) MEDPACE INVESTORS, LLC OFFER TO PURCHASE FOR CASH VESTED EMPLOYEE STOCK OPTIONS OF MEDPACE HOLDINGS, INC. THIS OFFER AND ALL WITHDRAWAL RIGHTS EXPIRE ON SEPTEMBER 3, 2019 AT 11:59 P.M., EASTERN TIME, UNLESS THE OFFER PERIOD IS EXTENDED AUGUST 5, 2019 Medpace Investors, LLC, a Delaware limited liability company (“we,” “us,” “our,” or “Medpace Investors |
|
| August 5, 2019 |
MEDPACE INVESTORS, LLC ELECTION FORM Instructions to Election Form EX-99.(a).(3) Exhibit (a)(3) MEDPACE INVESTORS, LLC ELECTION FORM Instructions to Election Form To elect to participate in the offer to purchase for cash certain employee stock options (the “Offer”), you must submit an Election Form in accordance with these instructions and the Offer to Purchase, dated August 5, 2019 (the “Offer to Purchase”). In order to participate in the Offer, a completed, sig |
|
| August 5, 2019 |
MEDP / Medpace Holdings, Inc. / Medpace Investors, Llc - SC TO-I SC TO-I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 MEDPACE HOLDINGS, INC. (Name of Subject Company (Issuer)) MEDPACE INVESTORS, LLC (Name of Filing Person (Offeror and Affiliate of Issuer)) Options to Purchase Common Stock, Par Value $0.01 Per Share (Title of Cl |
|
| July 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace |
|
| July 29, 2019 |
Medpace Holdings, Inc. Reports Second Quarter 2019 Results Exhibit 99.1 Media Contact: Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 [email protected] Investor Contact: [email protected] FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Second Quarter 2019 Results • Revenue of $214.1 million in the second quarter of 2019 increased 25.8% from revenue of $170.1 million for the comparable prior-year period, representing a backlog convers |
|
| July 29, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2019 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 29, 2019 |
MEDP / Medpace Holdings, Inc. CORRESP - - [KMK Letterhead] July 29, 2019 VIA EDGAR Ms. Linda Cvrkel Ms. Suying Li Securities and Exchange Commission Division of Corporation Finance Office of Beverages, Apparel and Mining 100 F. Street, NE Washington, D.C. 20549 Re: Medpace Holdings, Inc. Form 10-K for Fiscal Year Ended December 31, 2018 Filed February 26, 2019 Form 10-Q for Fiscal Quarter Ended March 31, 2019 Filed April 30, 2019 File No. |
|
| May 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 23, 2019 MEDPACE HOLDINGS, INC. |
|
| May 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2019 MEDPACE HOLDINGS, INC. |
|
| May 17, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2019 MEDPACE HOLDINGS, INC. |
|
| April 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace |
|
| April 29, 2019 |
Medpace Holdings, Inc. Reports First Quarter 2019 Results Exhibit 99.1 Media Contact: Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 [email protected] Investor Contact: [email protected] FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports First Quarter 2019 Results • Revenue of $200.7 million in the first quarter of 2019 increased 23.1% from revenue of $163.1 million for the comparable prior-year period, representing a backlog conversio |
|
| April 29, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2019 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commission F |
|
| April 16, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2019 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commissio |
|
| April 3, 2019 |
MEDP / Medpace Holdings, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 3, 2019 |
MEDP / Medpace Holdings, Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 11, 2019 |
MEDP / Medpace Holdings, Inc. / VANGUARD GROUP INC Passive Investment medpaceholdingsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Medpace Holdings Inc Title of Class of Securities: Common Stock CUSIP Number: 58506Q109 Date of Event Which Requires Filing of this Statement: February 28, 2019 Check the appropriate |
|
| February 26, 2019 |
List of Subsidiaries of Medpace Holdings, Inc. Exhibit 21.1 LIST OF SUBSIDIARIES OF MEDPACE HOLDINGS, INC. Jurisdiction of Organization Entity Name Delaware Medpace Acquisition, Inc. Delaware Medpace IntermediateCo, Inc. Ohio Imagepace, LLC Ohio Medpace Clinical Pharmacology LLC Ohio Medpace, Inc. Ohio Medpace Reference Laboratories LLC |
|
| February 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace Hold |
|
| February 25, 2019 |
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2018 Results Exhibit 99.1 Media Contact: Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 [email protected] Investor Contact: [email protected] FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2018 Results • Revenue was $192.1 million for the fourth quarter of 2018 and $704.6 million for the full year 2018. (Under ASC 605, fourth quarter 2018 net service revenue |
|
| February 25, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2019 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commissio |
|
| February 11, 2019 |
MEDP / Medpace Holdings, Inc. / VANGUARD GROUP INC Passive Investment medpaceholdingsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Medpace Holdings Inc Title of Class of Securities: Common Stock CUSIP Number: 58506Q109 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate |
|
| February 6, 2019 |
MEDP / Medpace Holdings, Inc. / Troendle August J. Activist Investment United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 (CUSIP Number) |
|
| February 6, 2019 |
EX-99.6 2 sched13da020619ex6.htm RULE 10B5-1 STOCK TRADING PLAN OF MEDPACE INVESTORS, LLC DATED NOVEMBER 15, 2018 EXHIBIT 6 Rule 10b5-l Trading Plan This Trading Plan (the "Trading Plan") is entered into on November 15, 2018 ("Seller's Adoption Date") between Medpace Investors LLC ("Seller") and UBS Financial Services Inc. ("UBSFS") for the purpose of selling, in accordance with Rule 10b5-1(c)(1) |
|
| October 30, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Med |
|
| October 30, 2018 |
Non-Employee Director Compensation Policy revised effective October 25, 2018 Exhibit 10.1 Medpace Holdings, Inc. Non-Employee Director Compensation Policy (Revised as of October 25, 2018) Non-employee members of the board of directors (the “Board”) of Medpace Holdings, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Policy (this “Policy”). The cash and equity compensation described in th |
|
| October 29, 2018 |
Medpace Holdings, Inc. Reports Third Quarter 2018 Results EX-99.1 2 medp-ex9916.htm EX-99.1 Exhibit 99.1 Media Contact: Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 [email protected] Investor Contact: [email protected] FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Third Quarter 2018 Results • Revenue was $179.3 million in the third quarter of 2018. (Under ASC 605, net service revenue of $124.0 million increased 25.6% from net se |
|
| October 29, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2018 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commission |
|
| October 2, 2018 |
MEDP / Medpace Holdings, Inc. / Troendle August J. Activist Investment United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 (CUSIP Number) |
|
| August 31, 2018 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2018 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Co |
|
| August 27, 2018 |
Amendment No. 7 to Schedule 13D United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 7)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Secur |
|
| August 24, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 22, 2018 MEDPACE HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 24, 2018 |
EX-1.1 2 d613165dex11.htm EX-1.1 Exhibit 1.1 5,224,997 Shares of Common Stock Medpace Holdings, Inc. UNDERWRITING AGREEMENT August 22, 2018 Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 Ladies and Gentlemen: Introductory. The stockholder named in Schedule A hereto (the “Selling Shareholder”) of Medpace Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to Morgan S |
|
| August 24, 2018 |
5,224,997 Shares Medpace Holdings, Inc. Common Stock 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-220306 PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED OCTOBER 23, 2017 5,224,997 Shares Medpace Holdings, Inc. Common Stock The selling shareholder named in this prospectus supplement is offering 5,224,997 shares of our common stock in this offering. We will not receive any proceeds from the sale of our common stock by the se |
|
| August 22, 2018 |
SUBJECT TO COMPLETION DATED AUGUST 22, 2018 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-220306 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not offer |
|
| August 13, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2018 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commission |
|
| August 10, 2018 |
Amendment No. 6 to Schedule 13D United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 6)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Secur |
|
| August 9, 2018 |
EX-1.1 2 d590002dex11.htm EX-1.1 Exhibit 1.1 Execution Version 4,500,000 Shares of Common Stock Medpace Holdings, Inc. UNDERWRITING AGREEMENT August 7, 2018 Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 Ladies and Gentlemen: Introductory. The stockholder named in Schedule A hereto (the “Selling Shareholder”) of Medpace Holdings, Inc., a Delaware corporation (the “Company”), proposes to |
|
| August 9, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 7, 2018 MEDPACE HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 9, 2018 |
4,500,000 Shares Medpace Holdings, Inc. Common Stock 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-220306 PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED OCTOBER 23, 2017 4,500,000 Shares Medpace Holdings, Inc. Common Stock The selling shareholder named in this prospectus supplement is offering 4,500,000 shares of our common stock in this offering. We will not receive any proceeds from the sale of our common stock by the se |
|
| August 8, 2018 |
MEDP / Medpace Holdings, Inc. / Troendle August J. - SCHEDULE 13D/A Activist Investment Schedule 13D/A United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 58506Q109 |
|
| August 8, 2018 |
EX-99.5 Exhibit 5 Rule 10b5-1 Trading Plan This Trading Plan (the “Trading Plan”) is entered into on 06/14/18 (“Seller’s Adoption Date”) (MM/DD/YYYY) between The August J. Troendle Revocable Trust (“Seller”) and UBS Financial Services Inc. (“UBSFS“) for the purpose of selling, in accordance with Rule 10b5- 1(c)(1) of the Securities Exchange Act of 1934 as amended (the “Exchange Act”), shares of co |
|
| August 7, 2018 |
SUBJECT TO COMPLETION DATED AUGUST 7, 2018 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-220306 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not offer |
|
| August 6, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2018 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commissi |
|
| July 31, 2018 |
MEDP / Medpace Holdings, Inc. 10-Q (Quarterly Report) 10-Q 1 medp-10q20180630.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commissio |
|
| July 30, 2018 |
Medpace Holdings, Inc. Reports Second Quarter 2018 Results Exhibit 99.1 Media Contact: Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 [email protected] Investor Contact: [email protected] FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports Second Quarter 2018 Results • Revenue was $170.1 million in the second quarter of 2018. (Under ASC 605, net service revenue of $117.8 million increased 24.6% from net service revenue of $94.6 million f |
|
| July 30, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2018 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 14, 2018 |
Amendment No. 5 to Schedule 13D United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 5)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Secur |
|
| June 13, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 11, 2018 MEDPACE HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 13, 2018 |
EX-1.1 Exhibit 1.1 Execution Version 3,000,000 Shares of Common Stock Medpace Holdings, Inc. UNDERWRITING AGREEMENT June 11, 2018 Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 Ladies and Gentlemen: Introductory. The stockholder named in Schedule A hereto (the “Selling Shareholder”) of Medpace Holdings, Inc., a Delaware corporation (the “Company”), proposes to sell to Morgan Stanley & C |
|
| June 13, 2018 |
3,000,000 Shares Medpace Holdings, Inc. Common Stock 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-220306 PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED OCTOBER 23, 2017 3,000,000 Shares Medpace Holdings, Inc. Common Stock The selling shareholder named in this prospectus supplement is offering 3,000,000 shares of our common stock in this offering. We will not receive any proceeds from the sale of our common stock by the se |
|
| June 11, 2018 |
SUBJECT TO COMPLETION DATED JUNE 11, 2018 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-220306 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not offer |
|
| June 8, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 8, 2018 MEDPACE HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 23, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2018 MEDPACE HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37856 32-0434904 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 8, 2018 |
Amendment No. 4 to Schedule 13D United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 4)* Medpace Holdings, Inc. (Name of Issuer) Common Stock (Title of Class of Secur |
|
| May 4, 2018 |
EX-1.1 2 d581478dex11.htm EX-1.1 Exhibit 1.1 EXECUTION VERSION 3,000,000 Shares of Common Stock Medpace Holdings, Inc. UNDERWRITING AGREEMENT May 2, 2018 Jefferies LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. The stockholder named in Schedule A hereto (the “Selling Shareholder”) of Medpace Holdings, Inc., a Delaware corporation (the “Company”), proposes to se |
|
| May 4, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 2, 2018 MEDPACE HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37856 32-0434904 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| May 4, 2018 |
3,000,000 Shares Medpace Holdings, Inc. Common Stock 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-220306 PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED OCTOBER 23, 2017 3,000,000 Shares Medpace Holdings, Inc. Common Stock The selling shareholder named in this prospectus supplement is offering 3,000,000 shares of our common stock in this offering. We will not receive any proceeds from the sale of our common stock by the se |
|
| May 2, 2018 |
SUBJECT TO COMPLETION DATED May 2, 2018 424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-220306 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement is part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not offer |
|
| May 1, 2018 |
MEDP / Medpace Holdings, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37856 Medpace |
|
| April 30, 2018 |
Medpace Holdings, Inc. Reports First Quarter 2018 Results EX-99.1 2 medp-ex9916.htm EX-99.1 Exhibit 99.1 Media Contact: Julie Hopkins Medpace Holdings, Inc. 513.579.9911 x12627 [email protected] Investor Contact: [email protected] FOR IMMEDIATE RELEASE Medpace Holdings, Inc. Reports First Quarter 2018 Results • Revenue was $163.1 million in the first quarter of 2018. (Under ASC 605, net service revenue of $108.4 million increased 15.6% from net se |
